Professional Supply 99% Raw Steroid Anabolic Hormone Powders Semi-finished injection oils ,Oral oils,SARMS and Peptides.
Payment & Shipping Terms:
|Product Name:||AOD-9604||Other Name:||AOD-9604|
|M.W.:||1815.08152||Packaging:||Foil Bag Or Vial|
|Shipping:||By Express (FedEx,UPS,DHL,EMS), By Air And By Sea||Payment:||Estern Union, Money Gram, T/T And Paypal|
Molecular formula: C78H123N23O23S2
Molar Mass: 1815.08152
CAS number: 221231-10-3
PubChem: CID 71300630
Synonyms: hGH Fragment 177-191, AOD-9604, 221231-10-3
AOD9604 is a peptide fragment (H Fragment 177-191) of the C-terminus of Human G H to which a tyrosine is added at the N-terminal end. Studies have suggested that AOD9604 is more effective than its predecessor AOD9401 in its ability to stimulate lipolytic (fat burning) and anti-lipogenic activity. Like G H, AOD9604 stimulates lipolysis (the breakdown or destruction of fat) and inhibits lipogenesis (prevents the transformation of fatty food materials into body fat) both in laboratory testing and in animals and humans. Recent clinical research studies have shown that AOD9604 did show a reduction of body fat in the mid abdominal area in both obese, over-weight, and average built people.
The Development of AOD9604 from Human G H
Investigators at Monash University discovered that the fat-reducing effects of GH appear to be controlled by a small region near one end of the GH molecule. This region, which consists of amino acids 177-191, is less than 10% of the total size of the GH molecule and appears to have no effect on growth or insulin resistance. It works by mimicking the way natural G H regulates fat metabolism but without the adverse effects on blood sugar or growth that is seen with unmodified G H.
The Fat Loss Properties of AOD 9604
In laboratory tests on fat cells from rodents, pigs, dogs, and humans, the H fragment released fat specifically from obese fat cells but not from lean ones, reduced new fat accumulation in all fat cells, enhanced the burning of fat. In rodents (rats and mice), H fragment reduced body fat in obese animals but, enhanced fat burning without changing food consumption or inducing growth (as it does not increase IGF levels) or any other unwanted G H effect. Recent research has shown AOD9604 to be an extremely potent and effective fat burner. Metabolic is developing AOD-9604 for the potential treatment of obesity. Research studies have shown that AOD9604 actually acts on the reduction of excessive adipose tissues such as those in the abdominal area, increase in muscle mass, and enhances the lipid content of the body.
These segments of the synthetic peptide AOD9604 have been researched for their in vivo effects in laboratory mice musculus. Results have shown that AOD9604 have resulted to a short-period increase in blood glucose and a more sustained increase in plasma insulin, together with other fragments such as 172-191, 177-191 and 178-191. In addition, the researchers have suggested that functionality of the peptide depends not only in the informational sequence but should also have the correct physical configuration (Ng and Borstein 1978). Also, AOD9604, being a region of high accessibility to proteases and also rich in proline, have been demonstrated to affect the conformational change in the cytoplasmic domain of the band 3 of erythrocyte membrane protein by serving as the hinge for the pivoting of the two subdomains. This then suggest that such residue is significant in conformational changes be serving as sites for peripheral protein binding in some body cells (Low et al. 1984).
AOD9604 - What is it?
AOD9604 is a peptide (a chain of amino acids) which was developed and patented by a company called Metabolic Pharmaceuticals in Australia in the late 1990s. AOD stands for "Anti Obesity Drug". This peptide has an amino acid sequence that mimics the lipolytic region of human G H (the region of this hormone thought to be responsible for burning fat) and it has been promoted variously as a weight loss supplement, as an aid to muscle and cartilage repair, and a treatment for osteoarthritis by its manufacturers. It is also known as lipotropin and Tyr-H fragment, and is generally available these days as a transdermal cream or an injectable.
AOD9604 - Why do people use it?
AOD9604 is promoted heavily by various manufacturers as a substance that is able to burn fat and assist in the repair of muscle and cartilage. The fact that this product derives from, and claims to mimic the effects of a powerfully anabolic banned substance provides a psychological incentive to many potential users, as does the attention drawn by the AFL "peptides" scandal of early 2013 and the subsequent report by the Australian Crime Commission (1).
Whilst AOD9604 is not approved by the Australian TGA, it can be legally obtained on a doctor's prescription and dispensed by a compounding pharmacy (2). This is true of many experimental substances, but it does big favours for the reputation of AOD9604, giving the impression that, like other drugs issued by the medical profession, it is an efficacious and high quality product. These reasons, when considered together, give a powerful impression that peptides are highly effective - they wouldn't ban them for no reason, would they?
Metabolic Pharmaceuticals have reported that recent in vitro trials have shown that AOD9604 may stimulate the growth of bone cells, and muscle and cartilage cells. These results have not yet been reproduced in animals or humans (4). There was a lot of speculation that Metabolic was providing AOD9604 to players at the Essendon Football Club as part of a secret clinical trial, but the company has flatly denied this claim, claiming it has not run any human trials since 2007 (2). AOD9604 has been scientifically proven safe and side-effect free (2), and is apparently very difficult to detect in the blood.
AOD9604 - The Negatives
The biggest negative, and this is a big one, is that AOD9604 has undergone very rigorous scientific testing, and has been found to have no effect in humans (3). When AOD9604 was first developed, it showed significant promise as a weight loss treatment. A special strain of obese mice supplemented with the peptide showed a reduction in weight, increased fat oxidation, and raised plasma glycerol, which are indicators of lipolysis, or fat burning (5). Subsequent studies in obese mice and rats attempted to show that the peptide works to burn fat in the same way as human G H, but found that this was not the case, meaning that the fact this peptide resembled H was meaningless. Scientists were unable to determine how this peptide was working in mice (6).
Metabolic turned their attention to human studies and performed six clinical trials on 925 people between 2001 and 2007. Not one of these trials showed that AOD9604 caused any weight loss or changes in body composition (3). In 2007, the company that owns Metabolic, Calzada, reported to their shareholders that AOD9604 showed no promise, and was being abandoned as a weight loss drug (2,3). The failure was blamed on inefficient absorption of the peptide drug through oral administration, as was used in the trials, even though rodent studies had shown the oral delivery route to be effective. At this point, Metabolic had sunk a massive $50 million into development and trials of AOD9604.
In 2010, the company heard word that bodybuilders were importing knock-off versions of the patent-protected peptide from China, and started licensing the manufacturing rights out to other companies in an attempt to compete, as this was determined to be a better course of action than attempting to sue the Chinese company for patent breach (7, 8). Desperate to recoup this investment, they invested a small additional amount into developing a technology that allowed the peptide to be absorbed through the skin, in collaboration with a company called Phosphagenics (4). The peptide was then licensed for use in BodyShaper, an anti-cellulite cream. Phosphagenics later dropped AOD9604 from BodyShaper, citing excessive expense and ineffectiveness (3).
When the AFL Peptides scandal hit, Calzada was forced to clarify the facts about AOD9604, and put out a cleverly worded press statement aimed at potential investors, concentrating on the fact that AOD9604 had been proven safe in large scale clinical trials (neglecting to mention a lack of effectiveness) and spoke of the success of AOD9604 on stimulating bone growth, and on cartilage and muscle cell repair in in-vitro trials (2,4). The black market uses for this peptide in muscle repair and treatment of obesity were also mentioned in the release, and it is clear through media reports on this scandal that Calzada gained traction from the profile boost (8).
If there's one thing that science has definitively said about AOD9604, it is that it is safe and has no side effects. Calzada, after trying the peptide out as an anti-obesity and anti-arthritic, has succeeded in having the peptide declared "Generally regarded as safe" by the FDA, which makes it legal to use as a food additive in America. Calzada, seemingly under no pretense that their product has pharmaceutical properties, is now trying to break into the US over the counter supplement and "Nutraceutical" market with AOD9604 (2,4). Interestingly, the compound has only been approved for use in levels of up to 1mg per day (2), whereas the doses used in trials generally hovered around 500ug/kg (5,6), which means a 100kg person was receiving 50mg of the peptide daily. There is no science behind the peptide, or the dosage, and Calzada themselves have previously said AOD9604 is not effective orally (2).
Press coverage and word of mouth has generated quite a bit of hype around AOD9604. Despite its popularity on the black market, there is no research into the safety and effect of injecting this peptide at high doses. Intriguingly, it is not currently in Calzada's interest to fight the black market production of AOD9604, even though it is a patented product. Calzada lack the funds to legitimately boost the reputation of this peptide through clinical trials, and there is a strong chance these would once again prove that AOD9604 has no effect. The good reputation this peptide currently enjoys is likely to provide strong leverage to its marketing as a food supplement in the United States.
AOD9604 Legal Status
Whilst not illegal to buy AOD9604 in Australia, AOD9604 does not have approval by the TGA, which means it is not allowed to be sold on the basis of it having any pharmaceutical or performance enhancing benefits. It has not been approved by any pharmaceutical authority worldwide, except for the previously mentioned "Generally Regarded As Safe" designation by the FDA. AOD9604 is currently classed by the World Anti Doping Agency (WADA) as a non-approved substance, which means it is not legal for use by athletes in competition. WADA policy is to ban all substances that are suspected of being performance-enhancing, even in the absence of clinical proof (1,2).
|CJC-1295 with DAC||2mg/vial||Oxytocin||2mg/vial|
|CJC-1295 without DAC||2mg/vial||TB500||2mg/vial|
|MT-1||10mg/vial||HGH Frag 176-191||2mg/vial|
Key Words :
Melanotan-1 Benefits, CJC1295 ,Ghrp-2/Ghrp-6 peptides blend, Melanotan 1
Europe, Melanotan 1 Peptides Source, Melanotan Price , Melanotan USA, Melanotan 1 and MT2,HGH Fragment 176 - 191 price, Mt-2 Melanotan II Europe,PT 141 source,TB 500 price,Where to buy IGF-1 LR3,BPC 157 USA,Follistatin 344,ACE 031 price,Epitalon price,Ipamorelin pirce,Hexarelin price
HGH Fragment 176 - 191:
MT-1 Melanotan l
Mt-2 Melanotan II:
PT 141 :
Cjc-1295 Without dac/with Dac
TB 500 :
Peg Mgf / PEG - MGF:
IGF-1 LR3 :
ACE 031 (ACVR2B):
Pentadecapeptide BPC 157: